Scalper1 News
Big pharma AbbVie (ABBV) got an upgrade Monday from BMO Capital Markets, which warmed to the potential of its pending acquisition. Analyst Alex Arfaei upgraded AbbVie to outperform from market perform, saying that growing awareness of biosimilar competition for flagship drug Humira have driven down the stock to reasonable levels. At the same time, he was overcoming his initial skepticism toward AbbVie’s $21 billion payout to acquire Pharmacyclics Scalper1 News
Scalper1 News